Targeting the root cause of autoimmune disease with unprecedented precision
Existing therapies either deplete all B-cells, reduce all IgG levels, or broadly suppress immune function—addressing symptoms while creating new vulnerabilities. Our disease-agnostic platform delivers unprecedented specificity: pathogenic B-cells eliminated, protective immunity intact. The result is a therapy designed not just to manage autoimmune disease, but to resolve it.
Current therapies broadly deplete B cells or reduce circulating antibodies, affecting both disease-causing and protective immune components without selectively addressing the underlying autoreactive response.
Simultaneously depletes disease-causing autoantibodies and eliminates the B cells that produce them
Grants, peer-reviewed publications and scientific updates charting our progress from discovery through clinical development.
Frequently asked questions about Canopy's science, pipeline, and mission.
Canopy’s first-in-class Antigen-Drug Conjugates (AgDCs) are designed to redefine treatment of antibody-mediated autoimmune diseases by replacing chronic immunosuppression with targeted immune reprogramming aimed at durable, disease-modifying, symptom-free remission.
